J
Jorge Salmerón
Researcher at National Autonomous University of Mexico
Publications - 254
Citations - 18818
Jorge Salmerón is an academic researcher from National Autonomous University of Mexico. The author has contributed to research in topics: Population & HPV infection. The author has an hindex of 50, co-authored 239 publications receiving 17370 citations. Previous affiliations of Jorge Salmerón include Mexican Social Security Institute & Harvard University.
Papers
More filters
Journal ArticleDOI
Dietary Fiber, Glycemic Load, and Risk of Non—insulin-dependent Diabetes Mellitus in Women
Jorge Salmerón,JoAnn E. Manson,Meir J. Stampfer,Graham A. Colditz,Alvin L. Wing,Walter C. Willett +5 more
TL;DR: The hypothesis that diets with a high glycemic load and a low cereal fiber content increase risk of diabetes in women is supported and grains should be consumed in a minimally refined form to reduce the incidence of diabetes.
Journal ArticleDOI
Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis
Guillermo M. Ruiz-Palacios,Irene Pérez-Schael,F. Raúl Velázquez,Hector Abate,Thomas Breuer,Sue Ann Costa Clemens,Brigitte Cheuvart,Felix Espinoza,Paul Gillard,Bruce L. Innis,Yolanda Cervantes,Alexandre da Costa Linhares,Pio Lopez,Mercedes Macias-Parra,Eduardo Ortega-Barria,Vesta Richardson,Doris Maribel Rivera-Medina,Luis Rivera,Belén Salinas,Noris Pavía-Ruz,Jorge Salmerón,Ricardo Rüttimann,Juan Carlos Tinoco,Pilar Rubio,Ernesto Nuñez,M. Lourdes Guerrero,Juan Pablo Yarzabal,Silvia Damaso,Nadia Tornieporth,Xavier Sáez-Llorens,Rodrigo Vergara,Timo Vesikari,Alain Bouckenooghe,Ralf Clemens,Beatrice De Vos,Miguel O'Ryan +35 more
TL;DR: Two oral doses of the live attenuated G1P[8] HRV vaccine were highly efficacious in protecting infants against severe rotavirus gastroenteritis, significantly reduced the rate of severe gastroenteropathy from any cause, and were not associated with an increased risk of intussusception.
Journal ArticleDOI
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
Jorma Paavonen,Paulo Naud,Jorge Salmerón,Cosette M. Wheeler,Song-Nan Chow,D Apter,Henry C Kitchener,Xavier Castellsagué,Julio Cesar Teixeira,S R Skinner,James Hedrick,Unnop Jaisamrarn,Genara Limson,Suzanne M. Garland,Anne Szarewski,Barbara Romanowski,Fred Y. Aoki,Tino F. Schwarz,Willy Poppe,Franz X. Bosch,David Jenkins,Karin Hardt,Toufik Zahaf,Dominique Descamps,Frank Struyf,Matti Lehtinen,Gary Dubin +26 more
TL;DR: The HPV- 16/18 AS04-adjuvanted vaccine showed high efficacy against CIN2+ associated with HPV-16/18 and non-vaccine oncogenic HPV types and substantial overall effect in cohorts that are relevant to universal mass vaccination and catch-up programmes.
Journal ArticleDOI
Dietary fiber, glycemic load, and risk of NIDDM in men
Jorge Salmerón,Alberto Ascherio,Eric B. Rimm,Graham A. Colditz,Donna Spiegelman,David J.A. Jenkins,Meir J. Stampfer,Alvin L. Wing,Walter C. Willett +8 more
TL;DR: Findings support the hypothesis that diets with a high glycemic load and a low cereal fiber content increase risk of NIDDM in men and suggest that grains should be consumed in a minimally refined form to reduce the incidence of N IDDM.
Journal ArticleDOI
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
Jorma Paavonen,David Jenkins,F. Xavier Bosch,Paulo Naud,Jorge Salmerón,Cosette M. Wheeler,Song Nan Chow,D Apter,Henry C Kitchener,Xavier Castellsagué,Newton Sérgio de Carvalho,S. Rachel Skinner,Diane M. Harper,James Hedrick,Unnop Jaisamrarn,Genara Limson,Marc Dionne,Wim Quint,Bart Spiessens,Pascal Peeters,Frank Struyf,Susan L. Wieting,Matti Lehtinen,Gary Dubin +23 more
TL;DR: The adjuvanted HPV16/18 vaccine showed prophylactic efficacy against cervical intraepithelial neoplasia (CIN) 2+ associated with HPV16 or HPV18 and thus could be used for cervical cancer prevention.